Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0
|
作者：
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构：
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 108
页数：11
相关论文
共 50 条
  • [41] Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification.
    Fu, Siqing
    Yao, Shuyang
    Yuan, Yuan
    Previs, Rebecca A.
    Elias, Anthony D.
    Carvajal, Richard
    George, Thomas J.
    Yuan, Ying
    Yamamura, Yuko
    Westin, Shannon
    Xing, Yan
    Dumbrava, Ecaterina E. Ileana
    Karp, Daniel D.
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Rodon, Jordi
    Takebe, Naoko
    Kunos, Charles
    Lu, Karen
    Keyomarsi, Khanda
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2021, 81 (13)
  • [42] Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
    Nagard, Mats
    Ah-See, Mei-Lin
    Strauss, James
    Wise-Draper, Trisha
    Safran, Howard P.
    Nadeau, Laura
    Edenfield, William J.
    Lewis, Lionel D.
    Ottesen, Lone H.
    Li, Yan
    Mugundu, Ganesh M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (03) : 193 - 203
  • [43] Adavosertib (AZD1775) does not prolong QT interval in patients with advanced solid tumors: A Phase I open-label study Lin
    Nagard, Mats
    Ah-See, Mei-Lin
    So, Karen
    Strauss, James
    Wise-Draper, Trisha
    Safran, Howard
    Wang, Ding
    Nadeau, Laura
    Edenfield, William
    Lewis, Lionel D.
    Rekic, Dinko
    Dota, Corina
    Ottesen, Lone
    Li, Yan
    Mugundu, Ganesh
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
    Serpico, Angela Flavia
    DAlterio, Giuseppe
    Vetrei, Cinzia
    Della Monica, Rosa
    Nardella, Luca
    Visconti, Roberta
    Grieco, Domenico
    CANCERS, 2019, 11 (06):
  • [45] Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
    Mats Någård
    Mei-Lin Ah-See
    James Strauss
    Trisha Wise-Draper
    Howard P. Safran
    Laura Nadeau
    William J. Edenfield
    Lionel D. Lewis
    Lone H. Ottesen
    Yan Li
    Ganesh M. Mugundu
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 193 - 203
  • [46] Analysis of the dose and schedule dependence of tumor kill in nonclinical tumour models after treatment with the WEE1 inhibitor AZD1775
    Yates, James William Thomas
    Cadogan, Elaine
    Hare, Jennifer I.
    Hughes, Adina M.
    Polanska, Urszula M.
    O'Connor, Mark J.
    Critchlow, Susan E.
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells
    Gomez, Miriam K.
    Thomson, John P.
    Grimes, Graeme R.
    Wang, Anderson T.
    Churchman, Michael
    O'Connor, Mark J.
    Gourley, Charlie
    Melton, David W.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (02) : 183 - 195
  • [48] Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models
    O'Connor, M. J.
    Odedra, R.
    Palakurthi, S.
    Hughes, A.
    Lai, Z.
    Kirschmeier, P.
    Zeng, Q.
    Zhou, S.
    Dharma, S.
    Ivanova, E.
    Wang, A.
    Pierce, A. J.
    Yates, J.
    Powell, S.
    Dougherty, B.
    Barrett, J. C.
    English, J.
    Jewsbury, P.
    Matulonis, U. A.
    Liu, J. F.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S142 - S142
  • [49] A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells
    Matheson, Christopher J.
    Venkataraman, Sujatha
    Amani, Vladimir
    Harris, Peter S.
    Backos, Donald S.
    Donson, Andrew M.
    Wempe, Michael F.
    Foreman, Nicholas K.
    Vibhakar, Rajeev
    Reigan, Philip
    ACS CHEMICAL BIOLOGY, 2016, 11 (04) : 921 - 930
  • [50] Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19 and CYP3A4 in patients with advanced solid tumors
    Nagard, Mats
    Ah-See, Mei-Lin
    So, Karen
    Strauss, James
    Wise-Draper, Trisha
    Safran, Howard
    Wang, Ding
    Nadeau, Laura
    Edenfield, William
    Lewis, Lionel D.
    Ottesen, Lone
    Li, Yan
    Mugundu, Ganesh
    CANCER RESEARCH, 2020, 80 (16)
12345